BioWorld

Feb. 8, 2002

Actelion Misses Endpoint In Chronic Heart Failure Study

The failure of Tracleer to meet primary endpoints in a Phase III trial of chronic heart failure patients could be a blessing in disguise for Switzerland-based Actelion Ltd. (BioWorld Today) Read More

Immunex, Genesis Form Pact To Research, Develop Molecules

Long-Sought Glaucoma Finally Found, Along With Slow-Onset Blindness-Provoking Mutations

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...